PEER Network Website Privacy Policy

PLEASE READ THIS PRIVACY POLICY CAREFULLY. This Privacy Policy tells you how United Therapeutics Corporation (“UTC”) and its contracted business partner, Health Advocacy Strategies LLC (“HAS”) (collectively, UTC and HAS are referred to in this Privacy Policy as “us” “we” “our”), protect and use information that we gather through this PEER Network website (“this website”). This website and this Privacy Policy are intended only for audiences in the United States.

UTC has developed the PEER Network and this website in partnership with HAS, who we consider to be a trusted business partner. We do not consider HAS to be a third party with respect to the PEER Network, and we may share your personally identifiable information with HAS as necessary to operate the PEER Network. HAS will abide by this Privacy Policy with respect to your information.

This Privacy Policy was last revised in December, 2015. We may change this Privacy Policy at any time and for any reason. We encourage you to review this Privacy Policy each time you visit this website.

By using this website, you agree to the terms of the most recent version of this Privacy Policy. Please read our Terms of Use to understand the general rules about your use of this website. Except as written in any other disclaimers, policies, Terms of Use, or other notices on this website, this Privacy Policy and the Terms of Use are the complete agreement between you and us with respect to your use of this website.

INTRODUCTION

We are posting this Privacy Policy to inform users as to how we use the information gathered by this website. For other important information concerning your use of this website, please refer to our Terms of Use. We respect the privacy of individuals who use this site. Users should understand, however, that by the very nature of the medium, their communications with us, such as postings to the site or e-mail, reveal their e-mail addresses and other potentially identifying information. The information we receive, and how we use it, depends on what you do when visiting our website. We collect and use your non-personal information (information that is not identifiable to you personally) differently than your personal information.

WHAT IS NON-PERSONAL INFORMATION?

Non-personal information is information we collect through this website that does not identify you as an individual person. It includes any of the following types of information:

WHAT DO WE DO WITH NON-PERSONAL INFORMATION?

Because non-personal information cannot identify you or be tied to you in any way, there are few restrictions on the ways that we can use or share non-personal information. Primarily, we will use this data to make enhancements to the website that are specifically tailored to improve the experience of the user community. One way that we use non-personal information is to demonstrate user trends on the website. Often, this is done by aggregating the data gleaned from non-personal information. This aggregated, de-identified data might be shared with outside parties who are employed to implement improvements to the site.

WHAT IS PERSONAL INFORMATION?

Personal information is information we collect through this website that we can use to specifically identify you, such as your:

In some places on this website, you have the opportunity to send us personal information about yourself. For example, you may fill out a registration form, a survey, or an e-mail form. Any personal information that you enter on this website will not be revealed to third parties or used for any purpose outside of the PEER Network except as provided for in this Privacy Policy.

HOW DO WE KEEP AND USE PERSONAL INFORMATION?

We comply with applicable privacy laws in the collection, storage, and use of your personal information. When you submit personal information through this website you are giving us permission to use your personal information for the purpose described below. Your information will never be shared with a third party, except as outlined below.

We may keep and use personal information we collect from you through this website to provide you with access to this website. In addition, we may keep and use your personal information:

Information Collection Specific to PEER Network

To participate in the PEER Network, you will be required to provide personal and contact information. This information is collected to provide you with a personalized experience and for internal program monitoring. It is not used for any other purposes or programs. Information provided will remain confidential in accordance with this Privacy Policy.

What Information is Collected?

We collect contact information, including your first name and first initial of your last name, e-mail, phone number(s), and state of residence. We also collect your age range, gender, the name of the physician who treats you for pulmonary arterial hypertension (PAH), and what UTC products (if any) you are currently receiving to treat your PAH. We ask you to indicate if you are a patient or caregiver and the purpose for choosing a PEER Mentor. Finally, we ask you to choose a User Name and password. From time to time, we also ask that you respond to surveys, which help to evaluate your satisfaction with the program.

How the Information is Used

We respect the information you submit. Your information will be used only for internal program monitoring. This may include looking at trends regarding current or planned UTC product use and discontinuation. Program staff will also use survey data to monitor trends in website user attitudes toward and satisfaction with the program. This includes average response time of Mentors, whether you might recommend this program to others, and your suggestions as to how we might improve the program.

We will never tie your name with your other personal information in our reporting and evaluation of the program. We will not use, sell, or assign your personal information for any purpose other than to communicate with you about the PEER Network, and to administer the PEER Network.

Your password will be used to keep your information secure and help us build your personalized webpage when you login.

Your age range, gender, User Name, and why you are seeking a Mentor will be shared with your Mentor. This information will help your Mentor better understand your circumstances and provide you with a meaningful experience.

DO WE EVER SHARE PERSONAL INFORMATION WITH THIRD PARTIES?

In the ordinary course of business, we may share some of your personal information with companies that we hire to perform services or functions on our behalf as necessary to administer the PEER Network. For example, we employ a company to develop and maintain this website. In this case, the company will have access to your personal information in the ordinary course of business. However, in this instance, and all instances in which your personal information is shared with a third party, we will not authorize them to keep, disclose, or use your information with others except for the purpose of providing the services we asked them to provide.

We will not sell, exchange, or publish your personal information, except in conjunction with a corporate sale, merger, dissolution, or acquisition, in which case, a surviving or acquiring company will be authorized to use your personal information for the purposes, and subject to the limitations, set forth in this Privacy Policy.

We may be legally compelled to release your personal information in response to a court order, subpoena, search warrant, law, or regulation. We may cooperate with law enforcement authorities in investigating and prosecuting website visitors who violate our rules or engage in behavior which is harmful to other visitors (or illegal).

We may disclose your personal information to third parties if we feel that the disclosure is necessary to:

WHAT HAPPENS IF THE PRIVACY POLICY CHANGES?

UTC reserves the right to change the terms of our Privacy Policy at any time in its sole discretion. Please periodically revisit this page to stay current on any changes and to update your preferences accordingly.

WHAT ABOUT PRIVACY ON OTHER WEBSITES?

This website may contain links to other websites. Some of those websites may be operated by UTC, and some may be operated by third parties. We provide the links for your convenience, but we do not review, control, or monitor the activities or privacy practices of websites operated by others, and we do not endorse, condone, adopt, or accept liability for any statements made on websites to which we provide links. This Privacy Policy does not apply to any other website, even those owned by UTC. We are not responsible for the performance of websites operated by third parties or for your business dealings with them. Therefore, whenever you leave this website, we recommend that you review each website's privacy practices and make your own conclusions regarding the adequacy of these practices.

DO WE EVER COMMUNICATE DIRECTLY WITH VISITORS WHO REGISTER THROUGH THIS WEBSITE?

Once you register through this website, we may contact you periodically by e-mail, mail, or telephone to administer the PEER Network. Additionally, if you ask a question or otherwise initiate a communication and request a response from us, we will send you a response via e-mail, mail, or telephone. Our response may include your personal information, including personal information about your health, your name, address, etc. We cannot guarantee that our e-mails to you will be secure from unauthorized interception.

THERE SPECIAL RULES ABOUT CHILDREN'S PRIVACY?

We care about protecting the online privacy of children. This website is not intended for use by children under the age of 18. We will not intentionally collect any personal information (such as a child's name or e-mail address) from children under the age of 18. If you are a child under age 18, please do not send us any information about yourself. If you think that we have collected personal information from a child under the age of 18, please contact us so that we can take appropriate remedial action.

WHAT ABOUT WEBSITE SECURITY?

We take reasonable steps to protect your personal information from loss, misuse, and unauthorized access, disclosure, alteration, or destruction. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Data you submit to this website, and information sent to or from us or you by e-mail or over the Internet and this website may not be secure, and you should therefore take special care in deciding what information you send to us via e-mail.

HOW TO CONTACT US

If you have questions or comments about this Privacy Policy, please contact: the United Therapeutics Corporate Compliance Department at 1-919-485-8350.

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Orenitram® (treprostinil) Extended-Release Tablets

INDICATION

Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram may improve your ability to exercise. It is not known if Orenitram is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION for Orenitram

Do not take Orenitram if you have severe liver problems.

Before you take Orenitram, tell your healthcare provider if you:

  • Have liver problems, diverticulosis, or any other medical conditions
  • Are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. You and your healthcare provider should decide if you will take Orenitram or breastfeed. You should not do both

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start or stop any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains the same ingredient, treprostinil. Know the medicines you take. Keep a list of them and the dose you take to show to your healthcare provider and pharmacist when you get a new medicine.

Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider. Stopping Orenitram suddenly may cause worsening of your PAH symptoms. If you miss two or more doses of Orenitram, call your healthcare provider. If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.

If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. Take Orenitram with food.

Orenitram can cause serious side effects, including an increased risk of bleeding. This risk could be increased if you are taking blood thinners such as warfarin.

The most common side effects of Orenitram include headache, diarrhea, nausea and flushing. These are not all of the possible side effects of Orenitram. Tell your doctor about any side effects that bother you, get worse over time, or do not go away.

OREISIdtcJAN16

Please see the Full Prescribing information and Patient Information for Orenitram.

For more information about Orenitram, visit www.orenitram.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Tyvaso® (treprostinil) Inhalation Solution

INDICATION

Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist, (ERA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). Your ability to do exercise decreases 4 hours after taking Tyvaso.

The effects of Tyvaso are unknown in patients under 18 years of age.

IMPORTANT SAFETY INFORMATION for Tyvaso

  • Tyvaso is breathed in (inhalable) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System.

Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a lung disease (such as asthma or chronic obstructive pulmonary disease (COPD)).
  • Have a lung infection.
  • Have liver or kidney problems, as your ability to tolerate Tyvaso may be affected.
  • Have low blood pressure, as Tyvaso may cause symptomatic hypotension (low blood pressure).
  • Are pregnant or plan to become pregnant. It is not known if Tyvaso will harm your unborn baby. Women who can become pregnant should use effective birth control while taking Tyvaso.
  • Are breast-feeding or plan to breast-feed. It is not known if Tyvaso passes into your breast milk.

It is important to tell your healthcare provider about all the medicines you may be taking, including prescription and non-prescription medicines, vitamins, and herbal supplements, as they may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. Especially tell your healthcare provider if you take any of these medicines:

  • Medicines that decrease blood clotting such as warfarin or heparin, as Tyvaso reduces the ability of your blood to clot (coagulate), and increases your risk for bleeding if you are taking blood thinners (anticoagulants).
  • Diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart disease), or other vasodilators (medications that lower blood pressure), as Tyvaso may increase your risk for hypotension (low blood pressure).
  • Gemfibrozil such as Lopid (for high cholesterol) or rifampin such as Rimactane, Rifadin, Rifamate or Rifater (for infection), as your Tyvaso dosage may need adjustment.

The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your healthcare provider about any side effects that bother you or do not go away. Your healthcare provider may be able to help you manage the side effects.

TYVISIdtcJUN16

Please see the Full Prescribing Information, Patient Package Insert, and Tyvaso Inhalation System Instructions for Use Manual.

For more information about Tyvaso, visit www.tyvaso.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Remodulin® (treprostinil) Injection

INDICATION

Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1), to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those in whom the risks are considered acceptable.

In patients with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of symptoms. The risks and benefits of each drug should be carefully considered before switching.

IMPORTANT SAFETY INFORMATION for Remodulin

  • Continuous intravenous (IV) infusions of Remodulin are delivered using a tube placed in a central vein within the chest. This type of delivery is associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
  • You should not stop or greatly reduce your Remodulin dose without consulting your doctor, as this may cause your PAH symptoms to worsen.
  • Other medical conditions and medicines may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug's effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking.
  • If you have liver or kidney problems, your ability to tolerate Remodulin may be affected.
  • If you are taking gemfibrozil (for high cholesterol), rifampin (for infection), or other drugs that affect liver enzymes, your doctor may need to adjust your Remodulin dosage.
  • Remodulin acts by lowering your blood pressure. In some cases your blood pressure may become too low and cause other side effects. If you also take other drugs that lower your blood pressure, the risk is increased. You should discuss all of your symptoms with your doctor, including those associated with low blood pressure.
  • Because Remodulin can reduce the blood's ability to clot, it may increase your risk of bleeding, especially if you are taking anticoagulants (blood thinners).
  • If you are pregnant, breast-feeding, or planning to become pregnant, talk with your doctor about whether you should take Remodulin.
  • Side Effects: In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness and swelling). These symptoms were often severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain. Other common side effects seen with either SC or IV Remodulin were headache, diarrhea, jaw pain, nausea, vasodilatation (widening of the blood vessels), and edema (swelling).

Please see the Full Prescribing Information for Remodulin.

For more information about Remodulin, visit www.remodulin.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Orenitram, Tyvaso, and Remodulin are registered trademarks of United Therapeutics Corporation.

All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.